Document Detail


Prognostic value of biomarkers in malignant melanoma.
MedLine Citation:
PMID:  9664152     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Biopsy specimens from 12 patients with metastatic melanoma were longitudinally analysed to evaluate changes in proliferation activity and CD4+/CD8+ ratios during the course of the disease. The primary tumours of the patients who subsequently had metastatic disease were also each matched with tumours from two controls whose disease remained localized, and were compared with regard to tumour proliferation. Immunohistochemistry was performed using the avidin-biotin complex (ABC) immunoperoxidase technique, using bcl-2, p53, mdm-2 and Ki-67 as the primary monoclonal antibodies, and the percentage of positively stained melanocytic cells was calculated. Frozen sections were also available from metastatic lesions excised from eight of our patients before treatment initiation and at the time of disease progression. These specimens were prepared for microscopy, and quantitative characterization of CD4+ (OKT 4a) and CD8+ (OKT 8) cells was performed. Compared with the localized melanomas bcl-2 expression was higher in those primary melanomas that later metastasized (P = 0.068, Wilcoxon; P = 0.038, median test). Mdm-2 and Ki-67 expression did not differ in the primary tumours of patients and controls, but a statistically significant trend was observed towards increasing expression with the progression of the disease (two-sided exact P-values: 0.04 and 0.05, respectively). Patients with a low Ki-67 index in their first metastasis had a better prognosis when compared with patients with high indexes (P = 0.008, log-rank). Furthermore, most patients with decreasing CD4+/CD8+ ratios had increasing p53 immunoreactivity. Our findings suggest that Ki-67 and bcl-2 may be useful for predicting the prognosis of melanoma patients. Mdm-2 is a new but promising marker in melanoma and deserves further evaluation.
Authors:
M Hernberg; J P Turunen; K von Boguslawsky; T Muhonen; S Pyrhönen
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Melanoma research     Volume:  8     ISSN:  0960-8931     ISO Abbreviation:  Melanoma Res.     Publication Date:  1998 Jun 
Date Detail:
Created Date:  1998-09-14     Completed Date:  1998-09-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9109623     Medline TA:  Melanoma Res     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  283-91     Citation Subset:  IM; X    
Affiliation:
Department of Internal Medicine, University of Helsinki, Finland. micaela.hernberg@helsinki.fi
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
CD4-CD8 Ratio
Disease Progression
Female
Humans
Immunoenzyme Techniques
Immunohistochemistry
Ki-67 Antigen / immunology,  metabolism
Male
Matched-Pair Analysis
Melanoma / diagnosis*,  immunology,  metabolism,  secondary
Middle Aged
Nuclear Proteins*
Prognosis
Proto-Oncogene Proteins / immunology,  metabolism
Proto-Oncogene Proteins c-bcl-2 / immunology,  metabolism
Proto-Oncogene Proteins c-mdm2
Skin Neoplasms / diagnosis,  immunology,  metabolism
Survival Rate
Tumor Markers, Biological / analysis*
Tumor Suppressor Protein p53 / immunology,  metabolism
Chemical
Reg. No./Substance:
0/Ki-67 Antigen; 0/Nuclear Proteins; 0/Proto-Oncogene Proteins; 0/Proto-Oncogene Proteins c-bcl-2; 0/Tumor Markers, Biological; 0/Tumor Suppressor Protein p53; EC 6.3.2.19/MDM2 protein, human; EC 6.3.2.19/Proto-Oncogene Proteins c-mdm2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Variability of cutaneous lymphatic flow rates in melanoma patients.
Next Document:  Fas/Fas ligand and hematopoietic progenitor cells.